PyroGenesis Canada (NASDAQ:PYRGF – Get Free Report) and Blueprint Medicines (NASDAQ:BPMC – Get Free Report) are both industrial products companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.
Insider & Institutional Ownership
0.0% of PyroGenesis Canada shares are held by institutional investors. 47.7% of PyroGenesis Canada shares are held by company insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings and target prices for PyroGenesis Canada and Blueprint Medicines, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PyroGenesis Canada | 0 | 0 | 0 | 0 | N/A |
| Blueprint Medicines | 1 | 5 | 11 | 2 | 2.74 |
Profitability
This table compares PyroGenesis Canada and Blueprint Medicines’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PyroGenesis Canada | -134.69% | -1,365.53% | -62.96% |
| Blueprint Medicines | -56.64% | -157.30% | -34.49% |
Earnings & Valuation
This table compares PyroGenesis Canada and Blueprint Medicines’ gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PyroGenesis Canada | $9.14 million | 11.76 | -$21.12 million | ($0.11) | -5.34 |
| Blueprint Medicines | $249.38 million | 21.99 | -$506.98 million | ($4.81) | -17.99 |
PyroGenesis Canada has higher earnings, but lower revenue than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than PyroGenesis Canada, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
PyroGenesis Canada has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.
Summary
Blueprint Medicines beats PyroGenesis Canada on 8 of the 14 factors compared between the two stocks.
About PyroGenesis Canada
PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.
About Blueprint Medicines
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for PyroGenesis Canada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PyroGenesis Canada and related companies with MarketBeat.com's FREE daily email newsletter.
